
Join us for the 34th Joint Glycobiology Meeting 2025 in Lille
Together, let’s contribute to scientific innovation in Glycobiology ! GLYcoDiag is sponsoring the event and will reward the best poster present by a young researcher
The complexity of glycans, their physicochemical properties and involvement in major biological functions make glycosciences the next challenge. Beside this initial expertise, we develop rapidly a growing interest regarding microbiota studies making additional specialty. These unique experiences helps our R&D customers from health (pharmaceutics, veterinary, biotechnology), cosmetics, diagnostics, food industry and environment domains, to speed up them projects.
Created in 2005, GLYcoDiag is an innovative company which has been the first to launch lectin array research, application and services studies in France.
We provide for our customers (private and academic laboratories) a unique and innovative library of glycosciences reagents and kits intended for the study of glycan interactions
- Natural and recombinant lectins
- Neoglycoproteins and neoglycoclusters
LEctPROFILE®gels, CarbPROFILE gels
Lectin based kits intended for ligands screening / comparison / detection
Research, characterization, and development of innovative glyco-molecules for therapeutics, cosmetics and nutraceutics applications.
Contracted research in glycoanalysis and glycomics to explore and map complex glycan structures.
Offering comprehensive glycoanalytical services to support biochemical research and development.
High throughput screening services to identify effective antimicrobial agents in cosmetics.
Skin microbiota dedicated models according to the environment and dysbiosis.
Studies of eucaryotic cells/microbiota adhesion





Together, let’s contribute to scientific innovation in Glycobiology ! GLYcoDiag is sponsoring the event and will reward the best poster present by a young researcher

Skin microbiota is key to skin balance and health. How can you ensure your ingredients respect it? At GLYcoDiag, we are skin microbiota experts. We design tailor-made in vitro co-culture

Enhanced rAAV2 liver targeting via GalNAc bioconjugation boosts gene delivery efficiency and safety for metabolic disease therapies. This study presents a new strategy to improve